Evidence map›Paper›PMID 28405787›Full record

ArticleInternational ophthalmology2018

Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.

Vasileios Konidaris, Zahra Al-Hubeshy, Konstantinos T Tsaousis, Konstantina Gorgoli, Somnath Banerjee, Theodoros Empeslidis

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Vasileios KonidarisLeicester Royal Infirmary, University Hospitals of Leicester, Infirmary Square, Leicester, LE1 5WW, UK. vasiliskon@hotmail.com.
Zahra Al-HubeshyLeicester Royal Infirmary, University Hospitals of Leicester, Infirmary Square, Leicester, LE1 5WW, UK.
Konstantinos T TsaousisLeicester Royal Infirmary, University Hospitals of Leicester, Infirmary Square, Leicester, LE1 5WW, UK.
Konstantina GorgoliLeicester Royal Infirmary, University Hospitals of Leicester, Infirmary Square, Leicester, LE1 5WW, UK.
Somnath BanerjeeLeicester Royal Infirmary, University Hospitals of Leicester, Infirmary Square, Leicester, LE1 5WW, UK.
Theodoros EmpeslidisLeicester Royal Infirmary, University Hospitals of Leicester, Infirmary Square, Leicester, LE1 5WW, UK.
Leicester Royal Infirmary · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the treatment outcome of switching from ranibizumab to aflibercept intravitreal injections in patients with macular oedema secondary to central retinal vein occlusion (CRVO).

methodsA prospective interventional study was conducted in a tertiary retina service in Leicester Royal Infirmary, UK, where patients with CRVO and associated macular oedema were recruited. First-line treatment involved three monthly ranibizumab injections. Non-responders were defined as patients who despite a minimum of three consecutive injections had persistent intraretinal fluid one month after the last injection. In these cases, a treatment change to aflibercept injections on a per-needed basis was decided. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured before and after switching of treatment. Follow-up period lasted for a minimum of 24 weeks after switching.

resultsTwenty-nine eyes of 29 patients with refractory macular oedema secondary to CRVO were included. All eyes had an average of 4.5 ranibizumab intravitreal injections in a mean period of 6 months without reduction in intraretinal fluid and/or no visual acuity gain. A significant decrease in mean CRT from 633.67 ± 242.42 to 234.62 ± 78.28 μm and improvement in mean BCVA from 1.34 ± 0.66 log MAR to 0.91 ± 0.73 log MAR were noticed after switching treatment to aflibercept. The average number of aflibercept injections needed for oedema resolution was 2.19.

conclusionsAflibercept is an effective alternative treatment for macular oedema secondary to CRVO refractory to ranibizumab. Good anatomical and functional result can be achieved with few injections. The maintenance of these results after 6 months is yet to be investigated.

Indexed as

Drug ToleranceVisual AcuityAgedAged, 80 and overAngiogenesis InhibitorsDrug SubstitutionFemaleFollow-Up StudiesHumansMacula LuteaMacular EdemaMaleMiddle AgedProspective StudiesRanibizumabReceptors, Vascular Endothelial Growth FactorafliberceptAngiogenesis InhibitorsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAfliberceptAnti-VEGFCRVORanibizumabSwitching

Identifiers

PMID28405787
OpenAlexW2606213351

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.